Enanta Pharmaceuticals (ENTA) earnings
In the quarter ended June 2026, Enanta Pharmaceuticals had revenue of $14M, down 21.6% on a year earlier, and diluted EPS of -0.67.
On August 10, 2026 it reported EPS of -0.67 against an estimate of -0.37 (missed).
The next report is expected on Monday, November 16, 2026, with EPS expected around -0.82.
Report dates
| Report | Date | Time | EPS estimate | EPS reported |
|---|---|---|---|---|
| Next | Mon Nov 16, 2026 | — | -0.82 | — |
| Last | Mon Aug 10, 2026 | — | -0.37 | -0.67 |
Dates from company announcements and exchange calendars; estimates are the consensus where available. See the full earnings calendar.
Quarterly results
The last 12 quarters from Enanta Pharmaceuticals's 10-Q and 10-K filings with the SEC. Growth is against the same quarter a year earlier. EPS here is GAAP diluted EPS as filed; the reported EPS compared with estimates above can be on the company's adjusted basis, so the two can differ.
| Quarter ended | Revenue | Growth | EPS (diluted) | Growth | Op. margin | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2026 | $14M | -21.6% | -0.67 | — | -120.0% | 2026-08-12 |
| Mar 31, 2026 | $17M | +15.0% | -0.45 | — | -69.1% | 2026-05-13 |
| Dec 31, 2025 | $19M | +9.8% | -0.42 | — | -60.5% | 2026-02-11 |
| Sep 30, 2025 | $15M | +3.5% | — | — | -121.6% | 2025-11-19 |
| Jun 30, 2025 | $18M | +1.9% | -0.85 | — | -103.2% | 2025-08-13 |
| Mar 31, 2025 | $15M | -12.5% | -1.06 | — | -164.3% | 2025-05-14 |
| Dec 31, 2024 | $17M | -5.8% | -1.05 | — | -138.8% | 2025-02-12 |
| Sep 30, 2024 | $15M | -22.8% | — | — | -204.4% | 2024-11-27 |
| Jun 30, 2024 | $18M | -4.9% | -1.07 | — | -134.6% | 2024-08-07 |
| Mar 31, 2024 | $17M | -4.2% | -1.47 | — | -192.1% | 2024-05-08 |
| Dec 31, 2023 | $18M | -23.7% | -1.58 | — | -193.8% | 2024-02-08 |
| Sep 30, 2023 | $19M | -6.8% | — | — | -163.9% | 2023-11-22 |
Questions
When does Enanta Pharmaceuticals report earnings?
Enanta Pharmaceuticals's next earnings report is expected on November 16, 2026.
How did Enanta Pharmaceuticals do last quarter?
In the quarter ended June 2026, Enanta Pharmaceuticals had revenue of $14M, down 21.6% on a year earlier, and diluted EPS of -0.67.
From Enanta Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.